Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease

Modern Rheumatology

Volumn 26, Issue 2, 2016, Pages 297-301

  Bannai, Ei ^a   Yamashita, Hiroyuki ^a   Kaneko, Shunta ^a   Ueda, Yo ^a   Ozaki, Takashi ^a   Tsuchiya, Haruka ^a   Takahashi, Yuko ^a   Kaneko, Hiroshi ^a   Kano, Toshikazu ^a   Mimori, Akio ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Adult onset Still's disease; Macrophage activation syndrome; Tocilizumab

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; CYCLOSPORIN; DEXAMETHASONE DERIVATIVE; ETANERCEPT; FERRITIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ADULT ONSET STILL DISEASE; ARTHRITIS; ARTICLE; BLEPHARITIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FERRITIN BLOOD LEVEL; FEVER; FOLLOW UP; HUMAN; LYMPHADENOPATHY; MACROPHAGE ACTIVATION SYNDROME; MALE; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PERICARDITIS; PRIORITY JOURNAL; RASH; REMISSION; SEPSIS; SORE THROAT; SPLENOMEGALY; CASE REPORT; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

EID: 84959504602     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.899178     Document Type: Article

References (27)

1. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006; 65(5): 564-72.
2. Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, et al. Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol. 1990; 17(8): 1058-63.
3. Aydintug AO, D'Cruz D, Cervera R, Khamashta MA, Hughes GR. Low dose methotrexate treatment in adult Still's disease. J Rheumatol. 1992; 19(3): 431-5.
4. Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol. 1996; 14(6): 653-5.
5. Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol. 2007; 3(6): 328-35.
6. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004; 31(11): 2189-98.
7. Fautrel B, Sibilia J, Mariette X, Combe B; Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis. 2005; 64(2): 262-6.
8. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, Burmester GR. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010; 69(2): 466-7.
9. de Boysson H, Février J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. Clin Rheumatol. 2013; 32(1): 141-7.
10. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011; 585(23): 3699-709.
11. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, et al. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 2012; 31(3): 569-74.
12. Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012; 22(5): 712-9.
13. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011; 21(1): 92-6.
14. Takahashi Y, Ochi H, Yanai A, Yamashita H, Itoh K, Mimori A. Successful tocilizumab therapy for adult onset Still's disease with intractable conditions over ten years. Nihon Naika Gakkai Zasshi. 2010; 99(1): 130-2.
15. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet. 2008; 371(9617): 998-1006.
16. Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F. Adult-onset Still's disease. Rheumatol Int. 2010; 30(7): 855-62.
17. Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011; 17(6): 315-7.
18. Bartoloni E, Alunno A, Luccioli F, Santoboni G, Gerli R. Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol. 2009; 27(5): 888-9.
19. Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010; 37(5): 967-73.
20. Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006; 65(12): 1596-601.
21. Kaneko K, Kaburaki M, Muraoka S, Tanaka N, Yamamoto T, Kusunoki Y, et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis. 2010; 13(4): e67-9.
22. Gianella S, Schaer DJ, Schwarz U, Kurrer M, Heppner FL, Fehr J, Seebach JD. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still's disease and concurrent macrophage activation syndrome. Am J Hematol. 2008; 83(5): 424-7.
23. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112(10): 3959-64.
24. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996; 129(5): 750-4.
25. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48(2): 124-31.
26. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol. 2009; 21(3): 224-30.
27. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007; 66(9): 1162-7.